Lytix Biopharma Investor Relations Material

Lytix Biopharma is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company specializes in using oncolytic peptides, which are designed to kill cancer cells and stimulate the immune system to generate a strong, systemic T-cell response. This approach aims to overcome the challenges of tumor heterogeneity, where variations in cancer cells within a tumor reduce the effectiveness of conventional immunotherapies. The company is headquartered in Oslo, Norway, and its shares are listed on the Oslo Stock Exchange.